Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OXL001
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Oxilio Announces Start of Its First Clinical Trial With OXL001
Details : OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.
Brand Name : OXL001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2022
Lead Product(s) : OXL001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OXL001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program
Details : Oxilio has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001.
Brand Name : OXL001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2022
Lead Product(s) : OXL001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
